spacer
home > pmps > winter 2018 > open, inhale, close
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Open, Inhale, Close

Open, inhale, close has become the Holy Grail of inhaler designers – anything more demanding being considered likely to negatively influence a patient’s desire or ability to correctly use an inhaler device. Therefore, these three steps set in motion the processes needed to defeat the anatomical and physiological barriers in the lungs and nose for delivery of a drug to a local receptor or one in a remote organ. In short, the job of a pharmaceutical aerosol researcher is to overcome the complex chemical, physical, and biological barriers to drug efficacy using a device patients can and will use. The barriers go beyond science; regulations, cost, human nature, and personal experience all play a role in determining if a patient will indeed open, inhale, close. Not even 30-year veterans of Respiratory Drug Delivery (RDD®) meetings can single-handedly accumulate the vast range of knowledge, skills, and experience needed to develop an inhaled product. Pulmonary and nasal product development demands interdisciplinary collaboration and the active involvement of the patient.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Richard Dalby and Joanne Peart
Co-organisers of RDD 2018
spacer
Richard Dalby
spacer
spacer
spacer
Joanne Peart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement